The rate of severe infections decreased from 2 infections to 0.2 infections per PYO after treatment with etuvetidigene autotemcel.
Doctors in the United Kingdom developed a groundbreaking new gene therapy that is giving hope to patients with aggressive ...
Backed by Italy-based Fondazione Telethon ETS, Waskyra, for Wiskott-Aldrich syndrome, is the first gene therapy from a ...
Doctors in the UK have developed a groundbreaking gene therapy using base editing to treat aggressive blood cancers once ...
The FDA has issued its stamp of approval to a new, cell-based option to treat Wiskott-Aldrich syndrome (WAS), marking the ...
Fondazione Telethon ETS' Waskyra has become the first gene therapy in the US for patients with Wiskott-Aldrich syndrome (WAS) ...
Based on initial positive results from HOPE-B, etranacogene dezaparvovec became the first gene therapy approved for adults ...
The Food and Drug Administration this week granted approval to a new gene therapy for a rare immune disorder, the maker of which is notably not a drug ...
Pharmaceutical Technology on MSN
Cell and gene therapy investment strategy pivots as funding dries up
Later-stage financing deals for cell and gene therapy companies reflects a broader derisking trend in the pharma industry.
Investment from XGEN Venture, British Business Bank, and a global biopharmaceutical company will support first-in-human Phase ...
Fondazione Telethon announced that FDA has approved its Biologics License Application (BLA) for Waskyra (etuvetidigene ...
A new wave of gene therapy treatments offer a new lease on life for people with inherited diseases such as haemophilia. But ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback